Mutual of America Capital Management LLC Sells 5,106 Shares of Johnson & Johnson $JNJ

Mutual of America Capital Management LLC reduced its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 1.7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 295,862 shares of the company's stock after selling 5,106 shares during the quarter. Johnson & Johnson comprises about 0.5% of Mutual of America Capital Management LLC's holdings, making the stock its 20th biggest holding. Mutual of America Capital Management LLC's holdings in Johnson & Johnson were worth $45,193,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. GFG Capital LLC purchased a new stake in Johnson & Johnson in the second quarter valued at approximately $35,000. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson in the first quarter valued at approximately $47,000. 1248 Management LLC purchased a new stake in Johnson & Johnson in the first quarter valued at approximately $48,000. von Borstel & Associates Inc. purchased a new stake in Johnson & Johnson in the first quarter valued at approximately $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in Johnson & Johnson in the first quarter valued at approximately $52,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $193.27 on Monday. The firm has a market cap of $465.45 billion, a PE ratio of 18.65, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The company's fifty day simple moving average is $180.49 and its two-hundred day simple moving average is $164.90.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. As a group, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson's payout ratio is presently 50.19%.

Wall Street Analyst Weigh In

JNJ has been the topic of several research reports. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Bank of America lifted their price target on shares of Johnson & Johnson from $198.00 to $204.00 and gave the stock a "neutral" rating in a research note on Wednesday, October 15th. Morgan Stanley set a $190.00 price target on shares of Johnson & Johnson in a research note on Wednesday. Royal Bank Of Canada reissued an "outperform" rating and set a $209.00 price target on shares of Johnson & Johnson in a research note on Friday, October 10th. Finally, Citigroup lifted their price target on shares of Johnson & Johnson from $213.00 to $215.00 and gave the stock a "buy" rating in a research note on Wednesday, October 15th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $199.88.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.